Literature DB >> 32819814

Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients.

Angela B Smith1, Cleo A Samuel2, Sean D McCabe3, Allison Deal4, Mattias Jonsson5, Dana E Mueller6, Zahra M Mahbooba4, Antonia V Bennett7, Arlene E Chung8, Matthew E Nielsen9, Hung-Jui Tan6, Eric Wallen6, Raj Pruthi10, Andrew Wang6, Ethan Basch11, Bryce B Reeve12, Ronald C Chen13.   

Abstract

OBJECTIVE: To assess the feasibility of enrollment and collecting patient-reported outcome (PRO) data as part of routine clinical urologic care for bladder and prostate cancer patients and examine overall patterns and racial variations in PRO use and symptom reports over time. SUBJECTS/PATIENTS AND METHODS: We recruited 76 patients (n = 29 Black and n = 47 White) with prostate or bladder cancer at a single, comprehensive cancer center. The majority of prostate cancer patients had intermediate risk (57%) disease and underwent either radiation or prostatectomy. Over half (58%) of bladder cancer patients had muscle invasive disease and underwent cystectomy. Patients were asked to complete PRO symptom surveys using their preferred mode [web- or phone-based interactive voice response (IVR)]. Symptom summary reports were shared with providers during visits. Surveys were completed at 3 time points and assessed urinary, sexual, gastrointestinal, anxiety/depression, and sleep symptoms. Feasibility of enrollment and survey completion were calculated, and linear mixed effects models estimated differences in outcomes by race and time.
RESULTS: Sixty three percent of study participants completed all PRO measures at all 3 time points. Black patients were more likely to select IVR as their survey mode (40% vs. 13%, P < 0.05), and less likely to complete all surveys (55% vs. 74%, P = 0.13). Patients using IVR were also less likely to complete all surveys (41% vs. 69%, P = 0.046).
CONCLUSIONS: Reported preferences for survey mode and completion rates differ by race, which may influence survey completion rates and highlight potential obstacles for equitable implementation of PROs into clinical care.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Patient-reported outcomes (PROs); Prostate cancer; Racial disparities

Mesh:

Year:  2020        PMID: 32819814      PMCID: PMC7736202          DOI: 10.1016/j.urolonc.2020.06.030

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  20 in total

1.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

Authors:  Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag
Journal:  JAMA       Date:  2017-07-11       Impact factor: 56.272

2.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.

Authors:  David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays
Journal:  J Clin Epidemiol       Date:  2010-08-04       Impact factor: 6.437

3.  Feasibility of integrating standardized patient-reported outcomes in orthopedic care.

Authors:  James D Slover; Raj J Karia; Chelsie Hauer; Zachary Gelber; Philip A Band; Jove Graham
Journal:  Am J Manag Care       Date:  2015-08       Impact factor: 2.229

4.  Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

Authors:  Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley
Journal:  J Natl Cancer Inst       Date:  2011-12-07       Impact factor: 13.506

5.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Authors:  J T Wei; R L Dunn; M S Litwin; H M Sandler; M G Sanda
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

6.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Authors:  Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2009-11-17       Impact factor: 13.506

7.  Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.

Authors:  Aaron D Falchook; Rebecca Green; Mary E Knowles; Robert J Amdur; William Mendenhall; David N Hayes; Juneko E Grilley-Olson; Jared Weiss; Bryce B Reeve; Sandra A Mitchell; Ethan M Basch; Bhishamjit S Chera
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

8.  Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI).

Authors:  Scott M Gilbert; David P Wood; Rodney L Dunn; Alon Z Weizer; Cheryl T Lee; James E Montie; John T Wei
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

9.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

10.  Symptom prevalence in lung and colorectal cancer patients.

Authors:  Anne M Walling; Jane C Weeks; Katherine L Kahn; Diana Tisnado; Nancy L Keating; Sydney M Dy; Neeraj K Arora; Jennifer W Mack; Philip M Pantoja; Jennifer L Malin
Journal:  J Pain Symptom Manage       Date:  2014-06-26       Impact factor: 3.612

View more
  1 in total

1.  Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study.

Authors:  Elizabeth J Polter; Nidhi Kohli; B R Simon Rosser; Kristine M C Talley; Christopher W Wheldon; Chris J Hoefer; Morgan Wright; Ryan Haggart; Darry Mitteldorf; Gudrun Kilian; Badrinath R Konety; Michael W Ross; William West
Journal:  J Sex Med       Date:  2022-02-04       Impact factor: 3.802

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.